Abstract:Antiretroviral therapy is highly effective in suppressing human immunodeficiency virus (HIV)1. However, eradication of the virus in individuals with HIV has not been possible to date2. Given that HIV suppression requires life-long antiretroviral therapy, predominantly on a daily basis, there is a need to develop clinically effective alternatives that use long-acting antiviral agents to inhibit viral replication3. Here we report the results of a two-component clinical trial involving the passive transfer of two HIV-specific broadly neutralizing monoclonal antibodies, 3BNC117 and 10-1074. The first component was a randomized, double-blind, placebo-controlled trial that enrolled participants who initiated antiretroviral therapy during the acute/early phase of HIV infection. The second component was an open-label single-arm trial that enrolled individuals with viraemic control who were naive to antiretroviral therapy. Up to 8 infusions of 3BNC117 and 10-1074, administered over a period of 24 weeks, were well tolerated without any serious adverse events related to the infusions. Compared with the placebo, the combination broadly neutralizing monoclonal antibodies maintained complete suppression of plasma viraemia (for up to 43 weeks) after analytical treatment interruption, provided that no antibody-resistant HIV was detected at the baseline in the study participants. Similarly, potent HIV suppression was seen in the antiretroviral-therapy-naive study participants with viraemia carrying sensitive virus at the baseline. Our data demonstrate that combination therapy with broadly neutralizing monoclonal antibodies can provide long-term virological suppression without antiretroviral therapy in individuals with HIV, and our experience offers guidance for future clinical trials involving next-generation antibodies with long half-lives.

Anti-HIV Antibody and Drug Combinations Exhibit Synergistic Activity Against Drug-Resistant HIV-1 Strains

Synergistic effect resulting from combinations of a bifunctional HIV-1 antagonist with antiretroviral drugs.

Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection

Systematic Identification of Synergistic Drug Pairs Targeting HIV

Combining New Non-Nucleoside Reverse Transcriptase Inhibitors (RTIs) with AZT Results in Strong Synergism against Multi-RTI-Resistant HIV-1 Strains

Anti-HIV Agents Inspired by Antibodies

Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A

No Antagonism or Cross-Resistance and a High Barrier to the Emergence of Resistance in Vitro for the Combination of Islatravir and Lenacapavir.

Combinations of the First and Next Generations of Human Immunodeficiency Virus (HIV) Fusion Inhibitors Exhibit a Highly Potent Synergistic Effect Against Enfuvirtide- Sensitive and -Resistant HIV Type 1 Strains

Combination anti-HIV antibodies provide sustained virological suppression

Interactions Between Different Generation HIV‐1 Fusion Inhibitors and the Putative Mechanism Underlying the Synergistic Anti‐hiv‐1 Effect Resulting from Their Combination

A novel preventive strategy against HIV-1 infection: combinatorial use of inhibitors targeting the nucleocapsid and fusion proteins

Synergistic Efficacy of Combination of Enfuvirtide and Sifuvirtide, the First- and Next-Generation Hiv-Fusion Inhibitors

Broad synergistic antiviral efficacy between a novel elite controller-derived dipeptide and antiretrovirals against drug-resistant HIV-1

Progress in Researches on Anti-HIV-1 Drugs and Their Fixed-dose Combination

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

A novel preventive strategy against HIV-1 infection: combinatorial use of inhibitors targeting the nucleocapsid and fusion proteins <subtitle>Combination of SAMT10 and SFT against HIV-1</subtitle>

Anti-HIV Drug Development Through Computational Methods

Combination Modes of Antiretroviral Drugs in Anti-Hiv Treatments

Two-drug regimens for HIV treatment

Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends.